Amyotrophic Lateral Sclerosis Treatment Market

Amyotrophic Lateral Sclerosis Treatment Market by Treatments (Medication, Stem Cell Transplant, and Others), Distribution Channels (Hospital Pharmacies, Retail Pharmacies, and Others), and Regions (Asia Pacific, North America, Latin America, Europe, and Middle East & Africa) - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast 2021 – 2028

  • Report ID: HC-858
  • Author: Growth Market Reports
  • Rating: 4.8
  • Total Reviews: 2
  • No. Of Pages: 186
  • Format:
  • Pub. Date: Upcoming
  • Share:

The global amyotrophic lateral sclerosis treatment market size is projected to expand at a significant CAGR during the forecast period, 2021–2028. The growth of the market is attributed to the increasing awareness about ALS, growing geriatric population, and rising incidence rate.
 

Amyotrophic Lateral Sclerosis Treatment Market Key Takeaways


Amyotrophic lateral sclerosis (ALS) disease is also known as Lou Gehrig's disease. It is a progressive neurodegenerative disorder that damages nerve cells present in the central nervous system and responsible for controlling the voluntary muscles. There are some common symptoms such as weakness as a result of a reduction in the arms or legs muscles size, muscle twitching, and stiff muscles. Around 50% of the total people suffering from amyotrophic lateral sclerosis might lose the capability to speak, swallow, walk, breath, and use their hands.

As stated by the National Institute of Neurological Disorders and Stroke (NINDS), ALS patients often die after within 3-5 years of failure of respiratory. Sporadic and familial are two types of ALS disease. The sporadic is most common type and holds around 90% of all cases in the U.S. Familial type of ALS is hereditary, in which there is about 50% of chance genetic mutation inheritance and gradually disorder is developed. In 30-40% of familial ALS patients the defect is usually found in the C9ORF72 gene. Frontotemporal dementia (FTD) condition is generated due to mutation in C9ORF72 gene, this condition is developed with ALS as comorbidity referred to as ALS-FTD.
There is no permanent cure for ALS disease. But there are some treatments such as stem cell therapies and medications for slows down the disease progression, management of the symptoms, and prevention of unnecessary complications. Changing lifestyle results in increasing risk of developing the disorder, which makes a demand of targeted treatment options and novel therapeutics approaches.

Market Trends, Drivers, Restraints, and Opportunities

  • Growing number of patients affected by ALS is a key factor driving the market growth over the forecast period.
  • Rising government initiatives for R&D of rare disease and favorable approvals from Food and Drug Administration (FDA) generates various opportunities for companies are expected to fuel the growth of the market.
  • Increase in launch of novel medicines, growth expenditure on healthcare, and well developed healthcare infrastructure are anticipated to propel the market growth.
  • Increase in strategic collaborations of research institutes and key companies for ALS treatment development, sedentary lifestyle, and rising risk of developing ALS are estimated to fuel the growth of the market.
  • High cost of treatment and lack of awareness about disease among people are major factors that can hamper the growth of ALS treatment market in the coming years.
  • Low availability of treatment and lower prevalence rate are expected to impede the market growth over the forecast period.

Scope of the Report

The report on the global amyotrophic lateral sclerosis treatment market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.

Attributes

Details

Report Title

Amyotrophic Lateral Sclerosis Treatment Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast

Base Year

2020

Historic Data

2018–2019

Forecast Period

2021–2028

Segmentation

Treatments (Medication, Stem Cell Transplant, and Others), Distribution Channels (Hospital Pharmacies, Retail Pharmacies, and Others)

Regional Scope

Asia Pacific, North America, Latin America, Europe, and Middle East & Africa

Report Coverage

Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast

Key Players Covered in the Report

Mitsubishi Tanabe Pharma Corporation, Otsuka Pharmaceutical Co., Ltd., BrainStorm Therapeutics, Biogen Inc., Corestem, AB Science, F.Hoffmann-La Roche AG, Biohaven Pharmaceutical, Sun Pharmaceutical, and Ionis Pharmaceuticals, Inc.

 

Market Segment Insights

Stem cell transplant segment is expected to expand at a rapid pace
In terms of treatments, the amyotrophic lateral sclerosis treatment market is segmented into medication, stem cell transplant, and others. The medication segment is expected to represent a key share of the market in the coming years. Only two drugs are approved for ALS treatment, Rilutek (riluzole), and Radicava (edaravone). The Nuedexta (dextromethorphan/quinidine) drug is approved by FDA for pseudobulbar affect treatment, comorbidity of ALS.

On the other hand, the stem cell transplant segment is anticipated to expand at a rapid pace during the forecast period owing to growing demand of advanced treatment and new approach. Various initiatives are taken by government authoritative bodies and the Collaborative ALS Drug Discovery Initiative (CADDI) for rapid development of novel drugs and treatments which is projected to increase in the number of clinical trials and introduction of pipeline drugs in coming years.
 

Amyotrophic Lateral Sclerosis Treatment Market By Treatment


Hospital pharmacies segment is projected to hold a key market share
Based on distribution channels, the market is divided into hospital pharmacies, retail pharmacies, and others. The hospital pharmacies segment is expected to hold a key share of the market during the forecast period. The need of multiple times visits and stays during ALS treatment is driving the segment growth. Large number of patients prefers hospital pharmacies and retail pharmacies. This is attributed to quick and easy access to various drugs and adequate products offered by these distribution channels.

Other distribution channels in ALS treatment market such as clinics, diagnostics laboratories, and online pharmacies. Online pharmacies are also growing owing to increasing popularity of e-commerce channels which offers multiple options including in-depth information about drugs.

Asia Pacific is expected to dominate the market
On the basis of regions, the amyotrophic lateral sclerosis treatment market is categorized as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. The market of North America is anticipated to expand at an impressive CAGR during the forecast period. The regional market growth can be attributed to huge demand of ALS drugs, high healthcare expenditure, established healthcare infrastructure, and favorable reimbursement policies. As per published data in Centers for Disease Control and Prevention (CDC) Morbidity and Mortality Weekly Report, in 2015 around 16,500 ALS were found in the U.S.

On the other hand, the market of Asia Pacific is expected to exhibit a rapid growth rate in the coming years. In this region, industry is witnessing a rising generation of revenue from riluzole generic manufacturers, majorly in emerging countries such as India and China. Increasing investment in R&D, promising initiatives by government and manufacturers, and plenty of unexplored opportunities are some major factors fuelling the market growth.
 

Amyotrophic Lateral Sclerosis Treatment Market By Regions

1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Amyotrophic Lateral Sclerosis Treatment Market Overview
  4.1. Introduction
     4.1.1. Market Taxonomy
     4.1.2. Market Definition
  4.2. Macro-Economic Factors
     4.2.1. Industry Outlook
  4.3. Amyotrophic Lateral Sclerosis Treatment Market Dynamics
     4.3.1. Market Drivers
     4.3.2. Market Restraints
     4.3.3. Opportunity
     4.3.4. Market Trends
  4.4. Amyotrophic Lateral Sclerosis Treatment Market - Supply Chain
  4.5. Global Amyotrophic Lateral Sclerosis Treatment Market Forecast
     4.5.1. Amyotrophic Lateral Sclerosis Treatment Market Size (US$ Mn) and Y-o-Y Growth
     4.5.2. Amyotrophic Lateral Sclerosis Treatment Market Size (000’ Units) and Y-o-Y Growth
     4.5.3. Amyotrophic Lateral Sclerosis Treatment Market Absolute $ Opportunity
5. Global Amyotrophic Lateral Sclerosis Treatment Market Analysis and Forecast by Region
  5.1. Market Trends
  5.2. Introduction
     5.2.1. Basis Point Share (BPS) Analysis by Region
     5.2.2. Y-o-Y Growth Projections by Region
  5.3. Amyotrophic Lateral Sclerosis Treatment Market Size and Volume Forecast by Region
     5.3.1. North America
     5.3.2. Latin America
     5.3.3. Europe
     5.3.4. Asia Pacific
     5.3.5. Middle East and Africa (MEA)
  5.4. Absolute $ Opportunity Assessment by Region
  5.5. Market Attractiveness/Growth Potential Analysis by Region
  5.6. Global Amyotrophic Lateral Sclerosis Treatment Demand Share Forecast, 2019-2026
6. North America Amyotrophic Lateral Sclerosis Treatment Market Analysis and Forecast
  6.1. Introduction
     6.1.1. Basis Point Share (BPS) Analysis by Country
     6.1.2. Y-o-Y Growth Projections by Country
  6.2. North America Amyotrophic Lateral Sclerosis Treatment Market Size and Volume Forecast by Country
     6.2.1. U.S.
     6.2.2. Canada
  6.3. Absolute $ Opportunity Assessment by Country
  6.4. Market Attractiveness/Growth Potential Analysis
     6.4.1. By Country
     6.4.2. By Product Type
     6.4.3. By Application
  6.5. North America Amyotrophic Lateral Sclerosis Treatment Demand Share Forecast, 2019-2026
7. Latin America Amyotrophic Lateral Sclerosis Treatment Market Analysis and Forecast
  7.1. Introduction
     7.1.1. Basis Point Share (BPS) Analysis by Country
     7.1.2. Y-o-Y Growth Projections by Country
     7.1.3. Latin America Average Pricing Analysis
  7.2. Latin America Amyotrophic Lateral Sclerosis Treatment Market Size and Volume Forecast by Country
      7.2.1. Brazil
      7.2.2. Mexico
      7.2.3. Rest of Latin America
   7.3. Absolute $ Opportunity Assessment by Country
  7.4. Market Attractiveness/Growth Potential Analysis
     7.4.1. By Country
     7.4.2. By Product Type
     7.4.3. By Application
  7.5. Latin America Amyotrophic Lateral Sclerosis Treatment Demand Share Forecast, 2019-2026
8. Europe Amyotrophic Lateral Sclerosis Treatment Market Analysis and Forecast
  8.1. Introduction
     8.1.1. Basis Point Share (BPS) Analysis by Country
     8.1.2. Y-o-Y Growth Projections by Country
     8.1.3. Europe Average Pricing Analysis
  8.2. Europe Amyotrophic Lateral Sclerosis Treatment Market Size and Volume Forecast by Country
     8.2.1. Germany
     8.2.2. France
     8.2.3. Italy
     8.2.4. U.K.
     8.2.5. Spain
     8.2.6. Russia
     8.2.7. Rest of Europe
  8.3. Absolute $ Opportunity Assessment by Country
  8.4. Market Attractiveness/Growth Potential Analysis
     8.4.1. By Country
     8.4.2. By Product Type
     8.4.3. By Application
  8.5. Europe Amyotrophic Lateral Sclerosis Treatment Demand Share Forecast, 2019-2026
9. Asia Pacific Amyotrophic Lateral Sclerosis Treatment Market Analysis and Forecast
  9.1. Introduction
     9.1.1. Basis Point Share (BPS) Analysis by Country
     9.1.2. Y-o-Y Growth Projections by Country
     9.1.3. Asia Pacific Average Pricing Analysis
  9.2. Asia Pacific Amyotrophic Lateral Sclerosis Treatment Market Size and Volume Forecast by Country
     9.2.1. China
     9.2.2. Japan
     9.2.3. South Korea
     9.2.4. India
     9.2.5. Australia
     9.2.6. Rest of Asia Pacific (APAC)
  9.3. Absolute $ Opportunity Assessment by Country
  9.4. Market Attractiveness/Growth Potential Analysis
     9.4.1. By Country
     9.4.2. By Product Type
     9.4.3. By Application
  9.5. Asia Pacific Amyotrophic Lateral Sclerosis Treatment Demand Share Forecast, 2019-2026
10. Middle East & Africa Amyotrophic Lateral Sclerosis Treatment Market Analysis and Forecast
  10.1. Introduction
     10.1.1. Basis Point Share (BPS) Analysis by Country
     10.1.2. Y-o-Y Growth Projections by Country
     10.1.3. Middle East & Africa Average Pricing Analysis
  10.2. Middle East & Africa Amyotrophic Lateral Sclerosis Treatment Market Size and Volume Forecast by Country
     10.2.1. Saudi Arabia
     10.2.2. South Africa
     10.2.3. UAE
     10.2.4. Rest of Middle East & Africa (MEA)
  10.3. Absolute $ Opportunity Assessment by Country
  10.4. Market Attractiveness/Growth Potential Analysis
     10.4.1. By Country
     10.4.2. By Product Type
     10.4.3. By Application
  10.5. Middle East & Africa Amyotrophic Lateral Sclerosis Treatment Demand Share Forecast, 2019-2026
11. Competition Landscape
  11.1. Global Amyotrophic Lateral Sclerosis Treatment Market: Market Share Analysis
  11.2. Amyotrophic Lateral Sclerosis Treatment Distributors and Customers
  11.3. Amyotrophic Lateral Sclerosis Treatment Market: Competitive Dashboard
  11.4. Company Profiles (Details: Overview, Financials, Developments, Strategy)
     11.4.1. Mitsubishi Tanabe Pharma Corporation
     11.4.2. Otsuka Pharmaceutical Co., Ltd.
     11.4.3. BrainStorm Therapeutics
     11.4.4. Biogen Inc.
     11.4.5. Corestem

Segments Covered in the Report
The global amyotrophic lateral sclerosis treatment market has been segmented on the basis of

Treatments

  • Medication
  • Stem Cell Transplant
  • Others

Distribution Channels

  • Hospital Pharmacies
  • Retail Pharmacies
  • Others

Regions

  • Asia Pacific
  • North America
  • Latin America
  • Europe
  • Middle East & Africa

Key Players

  • Mitsubishi Tanabe Pharma Corporation
  • Otsuka Pharmaceutical Co., Ltd.
  • BrainStorm Therapeutics
  • Biogen Inc.
  • Corestem
  • AB Science
  • F.Hoffmann-La Roche AG
  • Biohaven Pharmaceutical
  • Sun Pharmaceutical
  • Ionis Pharmaceuticals, Inc.

Key players competing in the amyotrophic lateral sclerosis treatment market include Mitsubishi Tanabe Pharma Corporation, Otsuka Pharmaceutical Co., Ltd., BrainStorm Therapeutics, Biogen Inc., Corestem, AB Science, F.Hoffmann-La Roche AG, Biohaven Pharmaceutical, Sun Pharmaceutical, and Ionis Pharmaceuticals, Inc.

Many major market players are implementing several business strategies including mergers, acquisitions, partnerships, collaborations, expansion into emerging counties, and product launches to enhance their market shares.
 

Amyotrophic Lateral Sclerosis Treatment Market Key Players

Buy Report